Garcia-Tsao G, Abraldes JG, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017;65:310–35.

Article  PubMed  Google Scholar 

Ke Q, He J, Cai L, et al. Safety and efficacy of interventional embolization in cirrhotic patients with refractory hepatic encephalopathy associated with spontaneous portosystemic shunts. Sci Rep. 2024;14:14848.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nardelli S, Riggio O, Gioia S, et al. Spontaneous porto-systemic shunts in liver cirrhosis: clinical and therapeutical aspects. World J Gastroenterol. 2020;26:1726.

Article  PubMed  PubMed Central  Google Scholar 

Chung W, Promrat K, Wands J. Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases. World J Hepatol. 2020;12:533.

Article  PubMed  PubMed Central  Google Scholar 

Elkrief L, Rautou PE, Sarin S, et al. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver Int. 2016;36:936–48.

Article  CAS  PubMed  Google Scholar 

Uojima H, Yamasaki K, Sugiyama M, et al. Quantitative measurements of M2BPGi depend on liver fibrosis and inflammation. J Gastroenterol. 2024;59:598–608. https://doi.org/10.1007/s00535-024-02100-3.

Article  CAS  PubMed  Google Scholar 

Fujimori N, Umemura T, Kimura T, et al. Serum autotaxin levels are correlated with hepatic fibrosis and ballooning in patients with non-alcoholic fatty liver disease. World J Gastroenterol. 2018;24:1239.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Iwadare T, Kimura T, Okumura T, et al. Serum autotaxin is a prognostic indicator of liver-related events in patients with non-alcoholic fatty liver disease. Commun Med. 2024;4:73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Simón-Talero M, Roccarina D, Martínez J, et al. Association between portosystemic shunts and increased complications and mortality in patients with cirrhosis. Gastroenterology. 2018;154:1694–705.

Article  PubMed  Google Scholar 

Elwir S, Rahimi RS. Hepatic encephalopathy: an update on the pathophysiology and therapeutic options. J Clin Transl Hepatol. 2017;5:142.

PubMed  PubMed Central  Google Scholar 

Fallahzadeh MA, Rahimi RS. Hepatic encephalopathy: current and emerging treatment modalities. Clin Gastroenterol Hepatol. 2022;20:S9–19.

Article  PubMed  Google Scholar 

Watanabe A. Portal-systemic encephalopathy in non-cirrhotic patients: classification of clinical types, diagnosis and treatment. J Gastroenterol Hepatol. 2000;15:969–79.

Article  CAS  PubMed  Google Scholar 

Nardelli S, Gioia S, Ridola L, et al. Radiological intervention for shunt related encephalopathy. J Clin Exp Hepatol. 2018;8:452–9.

Article  PubMed  PubMed Central  Google Scholar 

Laleman W, Simon-Talero M, Maleux G, et al. Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology. 2013;57:2448–57.

Article  PubMed  Google Scholar 

Lynn AM, Singh S, Congly SE, et al. Embolization of portosystemic shunts for treatment of medically refractory hepatic encephalopathy. Liver Transpl. 2016;22:723–31.

Article  PubMed  PubMed Central  Google Scholar 

Philips CA, Rajesh S, Augustine P, et al. Portosystemic shunts and refractory hepatic encephalopathy: patient selection and current options. Hepatic Med Evid Res. 2019. https://doi.org/10.2147/HMER.S169024.

Article  Google Scholar 

An J, Kim K, Han S, et al. Improvement in survival associated with embolisation of spontaneous portosystemic shunt in patients with recurrent hepatic encephalopathy. Aliment Pharmacol Ther. 2014;39:1418–26.

Article  CAS  PubMed  Google Scholar 

Choi WM, Yoo SY, Chang JI, et al. A model for predicting poor survival in patients with cirrhosis undergoing portosystemic shunt embolization. J Gastroenterol Hepatol. 2023;38:1629–36.

Article  PubMed  Google Scholar 

Mukund A, Choudhury SP, Tripathy TP, et al. Influence of shunt occlusion on liver volume and functions in hyperammonemic cirrhosis patients having large porto-systemic shunts: a randomized control trial. Hep Intl. 2023;17:150–8. https://doi.org/10.1007/s12072-022-10418-4.

Article  Google Scholar 

Ishikawa T, Shiratsuki S, Matsuda T, et al. Occlusion of portosystemic shunts improves hyperinsulinemia due to insulin resistance in cirrhotic patients with portal hypertension. J Gastroenterol. 2014;49:1333–41.

Article  CAS  PubMed  Google Scholar 

Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol. 2001;37:1344–50.

Article  CAS  PubMed  Google Scholar 

Park Y-H, Sohn M, Lee SY, et al. Two-year therapeutic efficacy and safety of initial triple combination of metformin, sitagliptin, and empagliflozin in drug-naïve type 2 diabetes mellitus patients. Diabetes Metab J. 2024;48:253–64.

Article  PubMed  PubMed Central  Google Scholar